DrugPatentWatch Database Preview

FORTOVASE Drug Profile

When do Fortovase patents expire, and when can generic versions of Fortovase launch?

Fortovase is a drug marketed by Hoffmann La Roche and is included in one NDA. There is one patent protecting this drug.

This drug has forty patent family members in thirty-four countries.

The generic ingredient in FORTOVASE is saquinavir. There is one drug master file entry for this compound. Additional details are available on the saquinavir profile page.

Summary for FORTOVASE

International Patents:	40
US Patents:	1
Applicants:	1
NDAs:	1
Bulk Api Vendors:	36
Clinical Trials:	8
Patent Applications:	4,412
Formulation / Manufacturing:	see details
Prior Art and Litigation Support	Order Prior Art and Litigation support for FORTOVASE
DailyMed Link:	FORTOVASE at DailyMed

Drug patent expirations by year for FORTOVASE

Generic Entry Opportunity Date for FORTOVASE

Generic Entry Date for FORTOVASE^: ➤ Sign Up* Constraining patent/regulatory exclusivity: ➤ Sign Up NDA: 020828 Dosage: CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Medical Subject Heading (MeSH) Categories for FORTOVASE

Cytochrome P-450 CYP3A Inhibitors
HIV Protease Inhibitors

Synonyms for FORTOVASE

(2S)-N-[(1S,2R)-3-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-1-benzyl-2-hydroxy-propyl]-2-(quinoline-2-carbonylamino)butanediamide
(2s)-N-[(2s,3r)-4-[(2s,3s,4as,8as)-3-(Tert-Butylcarbamoyl)-3,4,4a,5,6,7,8,8a-Octahydro-1h-Isoquinolin-2-Yl]-3-Hydroxy-1-Phenyl-Butan-2-Yl]-2-(Quinolin-2-Ylcarbonylamino)butanediamide
(2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide
(2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinolin-2-ylformamido)butanediamide
(3S-(2(1R(R),2S*),3I,4athetav,8athetav))-N(sup 1)-(3-(3-(((1,1-Dimethylethyl)amino)carbonyl)octahydro-2(1H)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)butanediamide
(S)-N-((IS)-I-((1R)-2-((3S,4aS,8aS)-3-(tert-Butylcarbamoyl)octahydro-2(1H)-isoquinolyl)-1-hydroxyethyl)phenethyl)-2-quinaldamidosuccinamide
(S)-N1-((2S,3R)-4-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-3-hydroxy-1-phenylbutan-2-yl)-2-(quinoline-2-carboxamido)succinamide
127779-20-8
131176-13-1
149845-06-7 (monomethanesulfonate (salt))
1hxb
2-[[2-methyl-3-(trifluoromethyl)phenyl]amino]pyridine-3-carboxylic acid
24223-EP2269989A1
24223-EP2272516A2
24223-EP2272825A2
24223-EP2298761A1
24223-EP2298783A1
24223-EP2305640A2
24223-EP2305680A2
24223-EP2314590A1
2fgu
2fgv
779S208
AB00514056
ABP000344
AC-26377
AC1L9ATC
AKOS000280831
AN-32602
BC210734
BDBM50213021
BIDD:GT0323
BIDD:PXR0010
BPBio1_001373
BRD-K09963420-066-03-4
BSPBio_001248
Butanediamide, N1-((1S,2R)-3-((3S,4aS,8aS)-3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1H)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (2S)-
Butanediamide, N1-(3-(3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1H)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (3S-(2(1R(R),2S*),3alpha,4aalpha,8aalpha))-
Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)-
C-23431
CC-34367
CHEBI:63621
CHEMBL114
CIS-N-TERT-BUTYL-DECAHYDRO-2-[2(R)-HYDROXY-4-PHENYL-3(S)-[[N-2-QUINOLYLCARBONYL-L-ASPARAGINYL]AMINO]BUTYL]-(4AS)-ISOQUINOLINE-3(S)-CARBOXAMIDE
CS-1180
D00429
DB01232
DTXSID6044012
Fortovase (TN)
Fortovase; SAQUINAVIR,RO 31-8959
Fortovase(TM)
GTPL4813
HMS2232L04
HSDB 7161
HY-17007
Invirase
Invirase(TM)(monomesylate)
L3JE09KZ2F
LS-187081
MLS001195635
MLS001304735
MRF-0000273
N-tert.butyl-decahydro -2- [2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl) -L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide
N-tert.butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide
N-tert.butyl-decahydro-2[2(R)-hydroxy-4-phenyl-3-(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide
N(1)-{(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-yl}-N(2)-(quinolin-2-ylcarbonyl)-L-aspartamide
N~1~-{(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-yl}-N~2~-(quinolin-2-ylcarbonyl)-L-aspartamide
N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[(1,1-Dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide
NCGC00091469-02
NP-SQV
NSC722663
PLCG-SQV
Prestwick0_001114
Prestwick1_001114
Prestwick2_001114
Prestwick3_001114
QNC-ASN-HPH-DIQ-NTB
QWAXKHKRTORLEM-UGJKXSETSA-N
Ro 31 8959
Ro 31-8959
Ro 31-8959/000
Ro 318959
Ro-31-8959
Ro-318959000
ROC
saguinavir
SAQUINAVIR
Saquinavir (JAN/USP/INN)
Saquinavir [USAN:USP:INN:BAN]
Saquinavir-poly(lactide-co-glycolide)
Saquinavir/
saquinavirmesylate(subjecttopatentfree)
SC-14020
Sch 52852
SCHEMBL6881
SMR000469157
SPBio_003114
SQV
SQV-poly(lactide-co-glycolide)
UNII-L3JE09KZ2F
W-5153
ZINC3914596

US Patents and Regulatory Information for FORTOVASE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hoffmann La Roche	FORTOVASE	saquinavir	CAPSULE;ORAL	020828-001	Nov 7, 1997		DISCN	Yes	No	➤ Sign Up	➤ Sign Up			Y	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

Expired US Patents for FORTOVASE

Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hoffmann La Roche	FORTOVASE	saquinavir	CAPSULE;ORAL	020828-001	Nov 7, 1997	➤ Sign Up	➤ Sign Up
Hoffmann La Roche	FORTOVASE	saquinavir	CAPSULE;ORAL	020828-001	Nov 7, 1997	➤ Sign Up	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

International Patents for FORTOVASE

Subscribe to access the full database, or try a Free Trial
Country	Patent Number	Estimated Expiration
South Korea	100446118	➤ Sign Up
Hong Kong	1042227	➤ Sign Up
China	1326335	➤ Sign Up
Peru	12402000	➤ Sign Up
Norway	20012384	➤ Sign Up
Germany	69919889	➤ Sign Up
Country	Patent Number	Estimated Expiration

Supplementary Protection Certificates for FORTOVASE

Subscribe to access the full database, or try a Free Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0034432	96C0048	Belgium	➤ Sign Up	PRODUCT NAME: SAQUINAVIR; REGISTRATION NO/DATE: EU/1/96/026/001 19961004
0432695	C970013	Netherlands	➤ Sign Up	PRODUCT NAME: SAQUINAVIR DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARD BAAR ZUURADDITIEZOUT, IN HET BIJZONDER HET MESYLAAT; REGISTRATION NO/DATE: EU/1/96/026/001 19961004
0432695	32/1996	Austria	➤ Sign Up	PRODUCT NAME: SAQUINAVIR UND SEINE SAEUREADDITIONSSALZE, INSBESONDERE SAQUINAVIRMESYLAT; REGISTRATION NO/DATE: EU/1/96/026/001 19961004
0432695	96C0044	Belgium	➤ Sign Up	PRODUCT NAME: SAQUINAVIR; REGISTRATION NO/DATE: EU/1/96/026/001 19961004
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Summary for FORTOVASE

Generic Entry Opportunity Date for FORTOVASE

Medical Subject Heading (MeSH) Categories for FORTOVASE

Synonyms for FORTOVASE

Make Better Decisions: Try a trial or see plans & pricing